在人类大动脉狭窄症中,C型尿素系统明显下调
Tuomas O Peltonen1, Panu Taskinen, Ylermi Soini
1Department of Pharmacology and Toxicology, University of Oulu, PO Box 5000, 90014 Oulu, Finland.
Circulation
|August 22, 2007
概括
大动脉狭窄显示了C型尿素 (CNP) 和其受体表达的减少,这表明CNP调节了大动脉的化. 这一发现影响了对心血管疾病进展的理解.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 血管病理生理学
背景情况:
- 大动脉的化与动脉样硬化有共同的特征.
- 尿素 (ANP,BNP,CNP) 涉及血管动脉样硬化.
- 在前列动脉中,天然尿素系统的表达以前是未知的.
研究的目的:
- 描述和比较人类大动脉中尿素系统的表达.
- 为了调查 natriuretic在大动脉狭窄中的作用.
主要方法:
- 反转录聚合酶链反应 (RT-PCR) 用于量化尿酸 (ANP,BNP,CNP) 的基因表达,加工酶 (furin,corin) 和受体 (NPR-A,NPR-B,NPR-C).
- 免疫组织化学,以定位CNP表达在大动脉组织内.
- 基因表达在正常,吐,有纤维化的吐和狭窄的大动脉的比较.
主要成果:
- 这三种 natriuretic (ANP,BNP,CNP) 都在主动脉中表达.
- 大动脉狭窄显示CNPmRNA水平显著降低 (92%的减少,P<0.001).
- 静脉表现出的基因表达减少 (54%的减少,P=0.04),尿素受体-A (78%的减少) 和尿素受体-B (76%的减少).
- CNP局部存在于膜内皮细胞和肌纤维细胞中.
结论:
- 尿素,它们的加工酶和受体都存在于人类的大动脉中.
- 大动脉狭窄与CNP,furin,尿素受体-A和尿素受体-B的显著下调有关.
- 这些发现表明,C型尿素 (CNP) 在大动脉结石化过程中起到膜调节器的作用.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...


